International applications to business schools soared as domestic demand softened - GMAC survey29/10/2022 KUALA LUMPUR, Oct 27 (Bernama) -- Total applications to graduate business schools dipped from the pandemic-level spikes, slipping 3.4 per cent year-on-year among a matched sample of programmes, according to the Graduate Management Admission Council (GMAC) survey report.
The GMAC 2022 Application Trends Survey revealed that this comes after application volumes increased 2.4 per cent year-on-year in 2020 amid the start of the pandemic and sustained that level of demand in 2021 when schools reported a 0.4 per cent year-on-year increase. As the pandemic’s effects on mobility lessened this admissions cycle, however, international applications saw a remarkable rebound, particularly for those applying to programmes in the United States (US). Most US programmes reported international application increases, especially full-time two-year MBA programmes (80 per cent of programmes) and STEM-designated programmes (61 per cent). “Similarly in Europe, most MBA programmes either saw stability or more applications from abroad this year,” GMAC said in a statement. The survey also revealed that applications to business master’s programmes ticked up, riding the wave of international interest. Global applications to business master’s programmes — including master in management, master of finance, and master of data analytics — grew year-on-year by 3.2 per cent. In addition, Asia has retained more talent in-region while Canada experienced a reverse in application trends. Business schools in the Asia region were able to attract otherwise mobile candidates during the pandemic, while Canadian programmes saw significant drops in both domestic and international applications. The survey was conducted between July and September with application figures submitted by 950 programmes of 264 business schools in 33 countries worldwide, aiming to examine the rapidly shifting landscape of demand for graduate management education programmes. An annual survey in its 24th year, the 2022 study reflected perhaps the end of the pandemic-disrupted years and offers insight into how the post-pandemic market may take shape. -- BERNAMA
0 Comments
In response to increased pressure on enterprises to stay globally compliant when engaging with freelancers and contractors, Worksome is expanding its offering to seven new markets across EMEA, APAC and North America.
NEW YORK, LONDON & COPENHAGEN, Denmark, Oct 28 (Bernama-BUSINESS WIRE) -- Worksome, an External Workforce Management platform helping enterprises compliantly hire and pay contractor workforces globally, today announced a major expansion into seven new markets, including Germany, France, Australia, Singapore, Canada, Ireland, and the United Arab Emirates. This move comes after an increase in demand to compliantly source and pay external workforces in new markets, and simplify indirect supply chains that are unnecessarily complex. In addition to the current solution which offers compliant hiring and payments to freelancers in 150+ countries, the market expansion will provide multilingual in-house support in additional time zones, and local compliance expertise and market knowledge. Worksome’s customers will benefit from further simplified, consistent processes across the globe when working with external talent, as well as the ability to share their contractor workforce internationally - with one cohesive overview at an executive level. “Companies need access to highly qualified global talent faster than ever to stay competitive. With this expansion, we are taking big steps to allow our customers to operate a truly global external workforce compliantly,” said Morten Petersen, CEO of Worksome. “We’re excited to expand our in-house support and expertise even further for our clients operating around the globe”. In July 2022, Worksome reported 3x YoY revenue growth for the third consecutive year. Similar growth is anticipated in their newly expanded markets as they continue to be a key global layer in the external workforce management space, challenging enterprises to look beyond legacy enterprise MSP and VMS contingent workforce solutions, and simplify their supply chains on a global scale. For more information on Worksome, please visit: https://www.worksome.com. mrem.bernama.com/viewsm.php?idm=44570 KUALA LUMPUR, Oct 27 (Bernama) -- Prestige Biopharma group, comprised of Prestige Biopharma Limited and Prestige Biologics Co Ltd, announced that it will be appearing at CPhI Frankfurt 2022 on Nov 1-3, at Messe Frankfurt, Germany. The Prestige group will showcase its latest antibody drug pipeline and innovative CDMO service at a large-scale independent booth, according to a statement. At the booth, clients and visitors are invited to take part in the experience zones and a transparent OLED display will be exhibited to highlight the EU-GMP certified facility and 154,000 liters of global-scale production capacity of Prestige Biologics in South Korea. “We are excited to provide an inside look into Prestige Biopharma group at CPhI 2022 and are looking forward to having meaningful partner discussions. “We will be introducing our capabilities for development and manufacturing of antibody and vaccine therapeutics, to support our partners to bring life-saving medicines to the patient,” said head of global business development of Prestige Biopharma, Dr Michael Ruppert. The Prestige group looks forward to the on-site collaboration with biopharmaceutical partners at CPhI Frankfurt 2022. Prestige Biopharma group will continue to pursue ‘innovation for life’ in every area which is the group’s business purpose, while ensuring corporate DNA, innovation, efficiency and agility, to ultimately create a difference for humanity. More details at www.prestigebio.com. -- BERNAMA LONDON, Oct 27 (Bernama-GLOBE NEWSWIRE) -- Arthur D. Little (ADL) has launched a report on current and future transformation in healthcare, and the effect these far-reaching changes will have on the life sciences and insurance sectors. To assess that from more than one perspective, ADL and Munich Re, a leading provider of reinsurance, primary insurance and insurance-related risk solutions, have pooled their expertise and recommendations.
The combination of aging populations, changing urban and work environments, technical innovations in data processing and analysis, and current advances in diagnosing and treating diseases will not only dramatically transform healthcare but also our way of living. Healthcare systems and wider society must therefore prepare for these innovations to ensure preparedness and greater resilience. Disruptive developments such as digitization, far-reaching advances in medical technology, and the latest findings in life sciences interrelate and reinforce each other to an unprecedented extent. Consequently, the report sets out how everyone within the ecosystem needs to collaborate around a common goal – bringing innovations to patients faster and pushing the boundaries of insurability. Describing the impacts of transformation and providing insights, imperatives and key takeaways for both the insurance and life sciences industries, the report focuses on opportunities in five key areas of healthcare: - Digital Health - Advanced therapeutics & new paradigms in treatments - Power of genes & omics - Mental health - Pandemic risk Dr. Ulrica Sehlstedt, Managing Partner, and Global Practice Leader, Healthcare & Life Sciences at Arthur D. Little, comments: “Innovation is driving a revolution at every step of the patient journey. This impacts every player within the life sciences and healthcare industry, including insurance companies. The imperative is on the whole ecosystem to work together to provide positive solutions and mitigate current and future risks, which is why we are delighted that Munich Re has contributed to bring together knowledge, experience and perspectives within this in-depth report.” Dr. Franziska Thomas, Partner and Head of Healthcare & Life Sciences of Arthur D. Little Germany, comments: “The last two years has seen an enormous acceleration in multiple areas of medicine – and indeed across wider society. The patient journey is transforming to become more personalized and decentralized. As this report explains, it is only through convergence between all areas within the ecosystem that solutions can be delivered to meet the rapidly changing needs of patients.” To download the report visit: https://tinyurl.com/mszkfz28 Further information from: Cate Bonthuys / Sue Glanville Catalyst Comms +44 7746 546773 [email protected] A pdf accompanying this announcement is available at: http://ml-eu.globenewswire.com/Resource/Download/703e8c10-23ce-43a1-8ad4-98c37003af32 SOURCE: Catalyst Comms Ltd. http://mrem.bernama.com/viewsm.php?idm=44568 KUALA LUMPUR, Oct 27 (Bernama) -- Uniphore, the global leader in Conversational Automation, announced it has been accepted into the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell programme for AWS Partners who provide software solutions that run on or integrate with AWS.
According to a statement, the programme helps partners drive new business and accelerate sales cycles by connecting the participating ISVs with the AWS Sales organisation. “We are delighted to be accepted into the AWS ISV Accelerate Program. This is yet another proof of the value our technology brings to enterprises and our commitment to our customers. “It’s also a testament of Uniphore being at the forefront of always delivering the most robust solutions through solid partnerships, like the one with the AWS Sales organisation,” said Vice President, CCaaS Ecosystem, Global Alliances & Partnerships at Uniphore, Kennedy Pereira. Through the AWS ISV Accelerate Program, Uniphore receives focused co-selling support from AWS, access to further sales enablement resources, reduced AWS Marketplace listing fees, and incentives for AWS Sales teams. The programme provides participating ISVs with access to millions of active AWS customers globally. Uniphore, whose conversational AI and automation products are used globally, went through AWS’s comprehensive review process, including an extensive technical review of Uniphore’s platform and architecture as well as validation of Uniphore’s benefits for enterprise-level customers. -- BERNAMA GEORGE CLINICAL RECRUITS MORE THAN 5,000 PATIENTS IN THE GLOBAL KIDNEY PATIENT TRIALS NETWORK27/10/2022 OVERLAND PARK, Ks., Oct 26 (Bernama-GLOBE NEWSWIRE) -- George Clinical, in close collaboration with The George Institute for Global Health, has recently announced the recruitment of more than 5,000 patients in its ground-breaking, first of its kind, Global Kidney Patient Trials Network (GKPTN) which will accelerate treatments for kidney disease. The concept for the GKPTN is a logical extension of George Clinical’s scientific and clinical operations leadership in the kidney space. In early 2020, the GKPTN enrolled its first patient with the purpose of developing a network of patients with chronic kidney disease (CKD) willing to participate in clinical research projects accessible through a single global chronic kidney disease platform. The GKPTN now has more than 140 sites in nine countries globally recruiting patients including Australia, China, Japan, USA, Canada, Argentina, Brazil, Spain and Italy with the full intention of continuing to expand the number of countries in the coming years.
The GKPTN aims to accelerate the development of new treatments and provide equitable benefits for the millions of people globally who suffer from chronic kidney disease and the many rarer kidney diseases associated with glomerular nephropathies. It is the rarer diseases that have seen increased focus of late from drug developers in the race to find treatments for these underserved patients. Responding to the needs of the researchers in the kidney space, George Clinical has made a commitment to prioritize the recruitment of patients into the network with these more rare glomerulonephropathies while still remaining focussed on the development of a master protocol under which future CKD trials can be run in a more efficient manner. George Clinical Chief Medical Officer, Maria Ali noted “Our ultimate goal is to grow the GKPTN to a total of 10,000 patients by the end of 2027 which will give us the bandwidth to support dozens of clinical trials in the kidney space. We are well on our way to achieving our goals as we seek to provide the infrastructure necessary to make recruitment timelines shorter and reduce the time to get needed treatments to patients.” There are a number of trials currently being supported by the GKPTN which are targeting treatments for CKD and glomerulonephropathy and the network has the capacity to support many more simultaneous trials. George Clinical, as the leading CRO in the kidney space will have an expanded presence to engage those in the industry interested in leveraging the network at the upcoming 2022 ASN Kidney Week in Orlando and briefings with scientific leaders and operations leads will be available. The development of the GKPTN was made possible through a generous grant from AstraZeneca and serves as a clear example of a true research partnership. About the Global Kidney Patient Trials Network With recruitment underway across nine countries and more than 140 sites with more than 5,000 patients already enrolled, the GKPTN allows for the ongoing and long term collection of critical data from patients suffering from kidney disease that will be analyzed for future treatment pathways and important interventions. The network establishes global infrastructure in a collaborative fashion to facilitate rapid and improved access to trials for patients with kidney disease. About George Clinical George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 400 people managing 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials. Website: https://www.georgeclinical.com LinkedIn: https://www.linkedin.com/company/george-clinical-pty-ltd Twitter: https://twitter.com/george_clinical Facebook: https://www.facebook.com/georgeclinical WeChat: https://mp.weixin.qq.com/. Matthew Reabold George Clinical 760-645-0496 [email protected] SOURCE: George Clinical http://mrem.bernama.com/viewsm.php?idm=44543 Chongming Water Secret SHANGHAI, Oct. 25, 2022 /Xinhua-AsiaNet/-- Water is believed the secret to the bumper harvest of high quality agricultural products in Chongming. The quality of water in the district maintains the same standard as the water quality of the Dongfeng Xisha Reservoir and Qingcaosha Reservoir -- the major drinking water sources for Shanghai residents. Since 2007, Chongming has initiated an industrial structure adjustment program in accordance with the requirements of its ecological island construction and the city's industrial structure adjustment. After over 10 years of effort, nearly 300 projects with out-dated production capacity have been shut down or relocated, including industries such as textile, printing and dyeing, and paper making, which are worried to cause pollution to the water environment. Through the unremitting water environment improvement project, Chongming's surface water quality compliance rate has reached 100 percent, and agricultural production continues to benefit. Mitten crab is one of the most renowned local aquatic products. Chongming crab is often hailed by gourmands for its attractive aroma and sweet taste. Wang Chenghui, a professor with Shanghai Ocean University, attributes Chongming's location at the mouth of the Yangtze River to this special flavor. The water quality here, where the fresh water and salty water meets, is rich in nutrients, Wang says. Although Chongming has a smaller water area and limited production capacity compared with nearby crab-breeding areas in Jiangsu and Anhui provinces, it can improve its crab quality to increase its popularity and value, Wang adds. Like the crab, high-quality rice is another signature produce of the district. In 2017, Chongming Rice, free from use of chemical fertilizers and pesticides, won the silver medal for its high quality in Shanghai. The allocation of farming area for green food within the district has reached 92 percent. At the Jiangfan Fruit and Vegetable Professional Cooperative in Chongming's Miaozhen Town, the model of "rice, fish and cray- fish" has been ongoing for many years. By raising fish, crayfish and other organisms in rice fields, weeds and pests can be minimized without the use of pesticides. In the nutritious water, fish and crayfish are well fed while rice produces a good yield, as well as an increased market value. According to Huang Guochao, head of the cooperative, the income per hectare on the farm is several times that of conventional rice planting. Source: Information Office of Shanghai Chongming District People's Government Image Attachments Links: Link: http://asianetnews.net/view-attachment?attach-id=432159 Caption: Chongming Water Secret Link: http://asianetnews.net/view-attachment?attach-id=432165 Caption: Chongming crab FcResolv™ NOG Models Provide Greater Clarity and More Translatable Data RENSSELAER, N.Y., Oct 25 (Bernama-GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known to confound results in antibody-based therapy studies. Murine FcγRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery. FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals. With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization. “Antibody-based therapies represent one of the fastest-growing classes of drugs, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “Taconic’s FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.” FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic’s Fc domain interacts with murine FcγRs as well as the false positives that result when FcγRs trigger residual murine immune activity. They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system. With more reliable answers, researchers can target their drug discovery investments more strategically and effectively. The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse®. The portfolio currently includes two models:
About Taconic Biosciences, Inc. Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world. Media Contact: Louise Baskin, Senior Director New Product Pipeline 303-432-2495 [email protected] SOURCE : Taconic Biosciences KUALA LUMPUR, Oct 21 (Bernama) -- TBO.com, a global travel distribution platform, is set to scale its business across the Asia-Pacific (APAC) region with two new leadership appointments and a significant showcase at ITB Asia 2022 in Singapore.
In a statement today, TBO announced the appointment of Vijayeta James to lead and expand its business in the APAC region and Patcharanee Somsamai to lead its supply organisation. “Bringing over 16 years of experience in business management, strategy and analytics, financial consulting, and academics, Vijayeta is responsible for leading and building sales and partner engagement strategies with a focus towards commercial transformation. “Patcharanee joins TBO from G2, a leading player in the group travel space, while her previous experience includes various roles at MG Holidays, Hotelbeds and Travelbullz,” it said. Meanwhile, it said that it will demonstrate at the ongoing travel trade show ITB Asia 2022 that travel agents and partners can leverage the platform for a simplified booking experience based on the growing demands from the region. “By participating in ITB Asia 2022, we aim to assert our global reach by onboarding veteran leaders onto our team, doubling our local employee base while also signing key partnerships for the region,” said its co-founder Gaurav Bhatnagar. In addition, TBO is also partnering with leading international hotel chains and the Saudi Tourism Authority to promote Saudi Arabia as a leisure destination among its APAC client base. With over one million hotels and 100,000 travel buyers across more than 100 countries, TBO continues to curate its travel content for the requirements of their customers, and deliver enjoyable travel experiences worldwide through artificial intelligence and machine learning algorithms. -- BERNAMA Stellar CX, better sales engagements are now possible with Uniphore X Platform
PALO ALTO, Calif., Oct 20 (Bernama-BUSINESS WIRE) -- Uniphore, the leader in conversational AI and automation, today announced the release of its enhanced Uniphore X platform, the industry’s most comprehensive platform that enables brands to accelerate and improve two key areas of their business: Customer Experience and Sales. With the latest enhancements to the platform, the conversations that happen between live or virtual agents as well as those happening between sales and prospects are now more effective and with minimal friction. Complete with conversational AI, emotion AI, knowledge AI, computer vision and robotic process automation (RPA), the power of the X platform lies in its robust architecture and the strong value proposition it offers customers. From designing frictionless customer journeys to enabling virtual sales scenarios, customers can expect the X platform to help them significantly improve their customers’ experiences and for sales teams, better engage with existing customers and new prospects. New capabilities embedded into the Uniphore X Platform support both the Uniphore U product line and the Uniphore Q for Sales product line. mrem.bernama.com/viewsm.php?idm=44508 |
Archives
April 2023
Categories |